Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Revenue (2016 - 2025)

Seres Therapeutics' Revenue history spans 10 years, with the latest figure at $351000.0 for Q3 2025.

  • For Q3 2025, Revenue changed N/A year-over-year to $351000.0; the TTM value through Sep 2025 reached $969000.0, up 1414.06%, while the annual FY2023 figure was $126.3 million, 1672.24% up from the prior year.
  • Revenue for Q3 2025 was $351000.0 at Seres Therapeutics, down from $618000.0 in the prior quarter.
  • Across five years, Revenue topped out at $126.7 million in Q3 2021 and bottomed at $64000.0 in Q4 2023.
  • The 5-year median for Revenue is $1.4 million (2022), against an average of $20.0 million.
  • The largest annual shift saw Revenue tumbled 97.28% in 2022 before it soared 10300.74% in 2023.
  • A 5-year view of Revenue shows it stood at $7.2 million in 2021, then plummeted by 86.5% to $975000.0 in 2022, then tumbled by 93.44% to $64000.0 in 2023, then soared by 865.62% to $618000.0 in 2024, then plummeted by 43.2% to $351000.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Revenue are $351000.0 (Q3 2025), $618000.0 (Q4 2024), and $64000.0 (Q4 2023).